Almasilate

Identification

Name
Almasilate
Accession Number
DB13595
Type
Small Molecule
Groups
Approved, Experimental
Description

Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [1].

Given that there are generally more widely available conventional antacids that are just as - if not more - effective than almasilate, almasilate products are only available in certain parts of Europe and/or Asia.

Structure
Thumb
Synonyms
  • Almasilato
  • Almasilatum
  • Magnesium aluminosilicate hydrate
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ohtas Isan AntacidAlmasilate (125 mg/1) + Calcium Carbonate (200 mg/1) + Sodium bicarbonate (200 mg/1)TabletOralOhta's Isan Co., Ltd2000-11-16Not applicableUs
Ohtas Isan AntacidAlmasilate (83.3 mg/1) + Calcium Carbonate (133.3 mg/1) + Sodium bicarbonate (133.3 mg/1)TabletOralOhta's Isan Co., Ltd2012-12-01Not applicableUs
International/Other Brands
Megalac
Categories
UNII
OZQ8O62H53
CAS number
71205-22-6
Weight
Average: 280.445
Monoisotopic: 279.8718534
Chemical Formula
Al2H2MgO9Si2
InChI Key
XFKLULFTFNRQOX-UHFFFAOYSA-N
InChI
InChI=1S/2Al.Mg.2O4Si.H2O/c;;;2*1-5(2,3)4;/h;;;;;1H2/q2*+3;+2;2*-4;
IUPAC Name
dialuminium(3+) ion magnesium(2+) ion hydrate disilicate
SMILES
O.[Mg++].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-]

Pharmacology

Indication

Almasilate is indicated for use as an antacid for the neutralization of excess stomach acid [8]. It is subsequently also used for the symptomatic treatment of diseases where it is necessary to neutralize acid in the stomach, for example, for treating stomach and duodenal ulcers or heartburn and stomach conditions caused by excess stomach acid [8].

Associated Conditions
Pharmacodynamics

Various non-prescription antacid products are available to the general public to purchase and use as a treatment for relieving the occasional, limited, and non-severe sensation of heartburn (or acid indigestion) that may frequently be associated with stomach indigestion (or dyspepsia) or gastroesophageal reflux disease (when stomach contents may rise back up into the esophagus and cause a taste of acid in the back of the mouth, among other symptoms) [3].

Subsequently, when excessive amounts of acids are produced in the stomach (either owing to indigestion or acid reflux, for example), the natural mucous barrier protecting the lining of the stomach can be damaged [3]. Antacids like almasilate consequently contain alkaline ions that chemically neutralize such stomach gastric acids, providing relief to heartburn, relieving pain, and reducing damage in the area [3].

Mechanism of action

Almasilate is a crystalline polyhydrate of aluminum/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer [5]. Specifically, the aluminosilicate minerals dissolve, and in doing so consume acidic hydrogen ions and release moieties like H4SiO4, Al3+, and other cations, including the magnesium associated with the compound [5]. Almasilate consequently contributes to the overall acid-neutralization by consuming acid hydrogen ion in this way [5]. Additionally, aluminum and other metals released from the original compound may also accumulate into secondary aluminum and magnesium based antacid like products that can act as secondary pH buffers [5].

Absorption

In regards to aluminum-containing antacids like the aluminum-magnesium complex almasilate, it is reported that the bioavailability of ingested aluminum from such antacids is only between 0.01-1% [5]. Additionally, while the optimal absorption of magnesium appears to be in the small intestine and particularly in the ileum and jejunum, with some absorption in the colon, it is believed that the transfer of magnesium from blood to extravascular space is quick and efficient [2].

Volume of distribution

The distribution of aluminum can occur in the bones, lungs, spleen, liver, kidney, nervous tissues, muscles, the blood itself, and the heart [6]. The highest levels of aluminum in mammalian tissues are found in the skeleton, lungs, kidneys, spleen, thyroid, and parathyroid glands [7].

Conversely, approximately half of the total magnesium in the body is distributed intracellularly in soft tissue and the other half is present in the bones [2]. Less than 1% of the total magnesium content is present in the blood [2]. In pregnant women, apparent volumes of distribution were evidently observed to range from 0.250 to 0.442 L/kg [2].

Protein binding

Once present in the bloodstream, 60% of aluminum is bound to transferrin proteins, 34% is bound to albumin protein, and the remainder is bound to citrate in the normal human blood serum [7]. Furthermore, 33% of serum magnesium is bound to protein, where approximately 75% of the protein bound fraction of magnesium is bound to albumin and the remaining 25% to globulins [2].

Metabolism

Once aluminum has entered the body, the mechanism by which it is metabolized is still not fully known [6]. Conversely, magnesium balance in the body is predominantly managed via a balance between intestinal absorption, exchange with bone, and renal excretion [4].

Route of elimination

The routes of excretion of aluminum in the body are mainly from the kidneys, which account for 95% of the elimination [6]. Magnesium is largely excreted in the urine [4].

Half life

Readily accessible data regarding the half-life of almasilate is not available.

Clearance

Readily accessible data regarding the clearance of almasilate is not available.

Toxicity

Readily accessible data regarding the toxicity of almasilate is not available.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Almasilate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Almasilate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineAlmasilate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAlmasilate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineAlmasilate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAlmasilate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Almasilate.Experimental, Illicit
AcepromazineAlmasilate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineAlmasilate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Almasilate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Almasilate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.Approved
AlimemazineAlmasilate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolAlmasilate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Almasilate.Approved
AmphetamineAlmasilate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Almasilate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Almasilate.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Almasilate.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Almasilate.Investigational
AtazanavirAlmasilate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Almasilate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Almasilate.Approved, Investigational
BenzphetamineAlmasilate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Almasilate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Almasilate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Almasilate.Approved, Investigational
BL-1020Almasilate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Almasilate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Almasilate.Approved
CaptoprilAlmasilate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Almasilate.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Almasilate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Almasilate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Almasilate.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Almasilate.Approved, Investigational, Vet Approved
ChlorphentermineAlmasilate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineAlmasilate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineAlmasilate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineAlmasilate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Almasilate.Approved, Investigational
CinoxacinAlmasilate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinAlmasilate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Almasilate.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Almasilate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Almasilate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Almasilate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Almasilate.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Almasilate.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Almasilate.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Almasilate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Almasilate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Almasilate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Almasilate.Approved, Investigational
DasatinibAlmasilate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Almasilate.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Almasilate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Almasilate.Approved
DemeclocyclineAlmasilate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Almasilate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Almasilate.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Almasilate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Almasilate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Almasilate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Almasilate.Vet Approved
DexmethylphenidateAlmasilate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineAlmasilate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionAlmasilate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Almasilate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Almasilate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Almasilate.Approved
Dipotassium phosphateAlmasilate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineAlmasilate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Almasilate.Approved
EnoxacinAlmasilate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Almasilate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Almasilate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Almasilate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Almasilate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Almasilate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Almasilate.Approved
Ferric CarboxymaltoseAlmasilate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateAlmasilate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Almasilate.Approved, Investigational
FleroxacinAlmasilate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Almasilate.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Almasilate.Approved, Investigational
FlumequineAlmasilate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Almasilate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Almasilate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Almasilate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Almasilate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Almasilate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Almasilate.Approved, Investigational
FluphenazineAlmasilate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Almasilate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Almasilate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Almasilate.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Almasilate.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Almasilate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Almasilate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Almasilate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Almasilate.Approved, Investigational, Withdrawn
FosinoprilAlmasilate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Almasilate.Approved, Investigational
GarenoxacinAlmasilate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinAlmasilate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Almasilate.Approved, Investigational
GemifloxacinAlmasilate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineAlmasilate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinAlmasilate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Almasilate.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Almasilate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Almasilate.Approved, Vet Approved
HydroxyamphetamineAlmasilate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Almasilate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Almasilate.Approved, Investigational
Iofetamine I-123Almasilate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronAlmasilate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranAlmasilate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateAlmasilate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidAlmasilate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Almasilate.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Almasilate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Almasilate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Almasilate.Approved
LevofloxacinAlmasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineAlmasilate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinAlmasilate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Almasilate.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Almasilate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Almasilate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Almasilate.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Almasilate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Almasilate.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Almasilate.Approved, Investigational
MephedroneAlmasilate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineAlmasilate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Almasilate.Approved
MesoridazineAlmasilate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineAlmasilate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Almasilate.Approved, Vet Approved
MethotrimeprazineAlmasilate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineAlmasilate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueAlmasilate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateAlmasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Almasilate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Almasilate.Experimental
MidomafetamineAlmasilate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineAlmasilate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Almasilate is combined with Misoprostol.Approved
MMDAAlmasilate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Almasilate.Approved, Vet Approved
MoricizineAlmasilate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MoxifloxacinAlmasilate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidAlmasilate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidAlmasilate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Almasilate.Investigational
NemonoxacinAlmasilate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Almasilate.Approved, Investigational
NorfloxacinAlmasilate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinAlmasilate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Almasilate.Investigational
Oxolinic acidAlmasilate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineAlmasilate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Almasilate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Almasilate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Almasilate.Approved
PazufloxacinAlmasilate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinAlmasilate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Almasilate.Approved
PerazineAlmasilate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineAlmasilate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineAlmasilate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidAlmasilate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidAlmasilate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Almasilate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Almasilate.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Almasilate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Almasilate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Almasilate.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Almasilate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Almasilate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Almasilate.Approved, Experimental, Investigational
ProchlorperazineAlmasilate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineAlmasilate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineAlmasilate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineAlmasilate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineAlmasilate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinAlmasilate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineAlmasilate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineAlmasilate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Almasilate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Almasilate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Almasilate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Almasilate.Approved, Investigational
RitobegronAlmasilate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinAlmasilate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Almasilate.Approved
RufloxacinAlmasilate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Almasilate.Approved
SitafloxacinAlmasilate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateAlmasilate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateAlmasilate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Almasilate.Approved
SparfloxacinAlmasilate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Almasilate.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Almasilate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Almasilate.Approved
TemafloxacinAlmasilate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineAlmasilate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiazinamAlmasilate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineAlmasilate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineAlmasilate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineAlmasilate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Almasilate.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Almasilate.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Almasilate is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Almasilate.Approved, Vet Approved
TriethylenetetramineAlmasilate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineAlmasilate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineAlmasilate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinAlmasilate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Almasilate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Almasilate.Approved
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Magaldrate and almasilate--complex buffering antacids. Drug Ther Bull. 1985 May 20;23(10):39-40. [PubMed:3888581]
  2. Ranade VV, Somberg JC: Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001 Sep-Oct;8(5):345-57. [PubMed:11550076]
  3. Ford AC, Moayyedi P: Dyspepsia. Curr Opin Gastroenterol. 2013 Nov;29(6):662-8. doi: 10.1097/MOG.0b013e328365d45d. [PubMed:24100727]
  4. Seo JW, Park TJ: Magnesium metabolism. Electrolyte Blood Press. 2008 Dec;6(2):86-95. doi: 10.5049/EBP.2008.6.2.86. Epub 2008 Dec 31. [PubMed:24459527]
  5. ScienceDirect: Aluminosilicate Profile [Link]
  6. University of Ottawa, Interdisciplinary Journal of Health Sciences: Human Health Effects of Dietary Aluminum [File]
  7. Healthy Canadians: Water Aluminum [File]
  8. Package Leaflet: Information for the patient, Megalac Almasilate 1 g /10 mL Suspension [File]
External Links
KEGG Drug
D07419
PubChem Compound
131704329
PubChem Substance
347829306
ChemSpider
32700646
Wikipedia
Almasilate
ATC Codes
A02AD05 — Almasilate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-2.6ChemAxon
pKa (Strongest Acidic)9.82ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area92.24 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity5.77 m3·mol-1ChemAxon
Polarizability5.14 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:44 / Updated on June 02, 2018 08:52